TD Cowen raised the firm’s price target on PTC Therapeutics (PTCT) to $50 from $46 and keeps a Hold rating on the shares. The firm updaed its model and corresponding estimates as its sum-of-the-part based price target goes higher.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics price target lowered at Cantor Fitzgerald, a top pick in 2025
- PTC Therapeutics Surpasses Revenue Guidance for 2024
- PTC Therapeutics provides potential key clinical, regulatory events in 2025
- PTC Therapeutics sees FY25 revenue $600M-$800M
- PTC Therapeutics sees FY25 revenue $600M-$800M, consensus $963.31M